Key result
Mendelian randomization links 33 plasma proteins to cardiac outcomes, including several mapped to oncological drugs.
Why the study?
Dysfunction of either ventricle can lead to heart failure and subsequent morbidity and mortality, prompting the identification of druggable proteins influencing cardiac structure and function.
Which plasma proteins are associated with cardiac structure, function, and heart failure outcomes?
Observational (n=36,548)
Yes
Which plasma proteins are associated with cardiac structure, function, and heart failure outcomes?
Mendelian randomization identifies 33 plasma proteins associated with cardiac structure and function, highlighting potential new drug targets for heart failure and mechanisms for cancer therapy-induced cardiotoxicity.
Answers are grounded in this paper and cite their sources.
May inform protein target selection for heart failure therapies; leaves open prospective validation of effects.
Dysfunction of either the right or left ventricle can lead to heart failure (HF) and subsequent morbidity and mortality. We performed a genome-wide association study (GWAS) of 16 cardiac magnetic resonance (CMR) imaging measurements of biventricular function and structure. Cis- Mendelian randomization (MR) was used to identify plasma proteins associating with CMR traits as well as with any of the following cardiac outcomes: HF, non-ischemic cardiomyopathy, dilated cardiomyopathy (DCM), atrial fibrillation, or coronary heart disease. In total, 33 plasma proteins were prioritized, including repurposing candidates for DCM and/or HF: IL18R (providing indirect evidence for IL18), I17RA, GPC5, LAMC2, PA2GA, CD33, and SLAF7. In addition, 13 of the 25 druggable proteins (52%; 95% confidence interval, 0.31 to 0.72) could be mapped to compounds with known oncological indications or side effects. These findings provide leads to facilitate drug development for cardiac disease and suggest that cardiotoxicities of several cancer treatments might represent mechanism-based adverse effects.
No takes yet. Share an insight, caveat, or question.
Schmidt et al. (2023) conducted an observational in Cardiac structure and function (n=36,548). Genetically proxied plasma proteins was evaluated on Cardiac magnetic resonance measurements and cardiac outcomes. Mendelian randomization identified 33 plasma proteins associated with cardiac traits and outcomes, including 13 druggable proteins mapped to compounds with known oncological indications or side effects.
Synapse has enriched 10 related papers. Consider them for comparative context: